VendorMark said:They are two different exemptions from the same federal requirements and they buy different things.
I read this differently from VendorMark, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
Correct me if the detail matters more than I have assumed.
CarlaRPh_TPA said:My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $930 | FDA-approved | N/A (pharma) |
| 503B Compounding | $160 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $120 | Patient-specific | Varies |
| Research peptide | $45 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.
NeuroNate said:A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide shortage ongoing, tirzepatide partially resolved. This directly impacts compounding availability.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne thing that is still open after adam_van’s answer:
Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?
Closing the loop on my own question.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.